New England Journal of Medicine

News

NEJM responds to claims of bias from Justice Department

The New England Journal of Medicine (NEJM) has hit back at assertions of bias in its editorial policies from Republican activist Edward Martin Jr.

News

Eisai's full lecanemab phase 3 trial results for Alzheimer's...

Following the news of two lecanemab-related deaths reported on the eve of the C

News

J&J jumps on the MFN pricing train

Johnson & Johnson is the latest pharma group to agree a Most-Favoured Nation (MFN) drug pricing deal with the Trump administration to avert tariffs.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Physicians walking and using tablet devices

How to meet your physicians where they are online

A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.

New England Journal of Medicine

Editor's Picks